

Siegfried Janz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3463009/publications.pdf>

Version: 2024-02-01

115
papers

3,649
citations

147726

31
h-index

143943

57
g-index

117
all docs

117
docs citations

117
times ranked

4789
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicolour spectral karyotyping of mouse chromosomes. <i>Nature Genetics</i> , 1996, 14, 312-315.	9.4	307
2	Regulation of AID expression in the immune response. <i>Journal of Experimental Medicine</i> , 2007, 204, 1145-1156.	4.2	229
3	Burkitt Lymphoma in the Mouse. <i>Journal of Experimental Medicine</i> , 2000, 192, 1183-1190.	4.2	195
4	Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPC, RANKL and M-CSF. <i>Molecular Cancer</i> , 2007, 6, 71.	7.9	155
5	Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 211-223.	1.5	136
6	IL-6 transgenic mouse model for extraosseous plasmacytoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1509-1514.	3.3	123
7	HHV-8 encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. <i>Blood</i> , 2012, 119, 5173-5181.	0.6	110
8	Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice. <i>Cancer Research</i> , 2005, 65, 1306-1315.	0.4	105
9	Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 7313-7323.	3.2	101
10	NF- κ B/STAT3/PI3K signaling crosstalk in iMyc $\frac{1}{4}$ B lymphoma. <i>Molecular Cancer</i> , 2010, 9, 97.	7.9	99
11	Myc translocations in B cell and plasma cell neoplasms. <i>DNA Repair</i> , 2006, 5, 1213-1224.	1.3	92
12	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. <i>Journal of Clinical Investigation</i> , 2004, 113, 1763-1773.	3.9	84
13	Prevalence and frequency of circulating t(14;18) ϵ MBR translocation carrying cells in healthy individuals. <i>International Journal of Cancer</i> , 2009, 124, 958-963.	2.3	82
14	HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. <i>Journal of Hematology and Oncology</i> , 2021, 14, 54.	6.9	75
15	Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. <i>Journal of Clinical Investigation</i> , 2004, 113, 1763-1773.	3.9	70
16	Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1140-1150.	1.9	68
17	Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma. <i>Cancer Research</i> , 2015, 75, 594-604.	0.4	65
18	B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18956-18960.	3.3	64

#	ARTICLE	IF	CITATIONS
19	Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. <i>Immunologic Research</i> , 2014, 59, 188-202.	1.3	57
20	Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. <i>Leukemia Research</i> , 2013, 37, 146-154.	0.4	56
21	NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. <i>Oncotarget</i> , 2014, 5, 11986-11997.	0.8	54
22	IL-6 and MYC collaborate in plasma cell tumor formation in mice. <i>Blood</i> , 2010, 115, 1746-1754.	0.6	49
23	COMBO-FISH: specific labeling of nondenatured chromatin targets by computer-selected DNA oligonucleotide probe combinations. <i>BioTechniques</i> , 2003, 35, 564-577.	0.8	47
24	Deletional remodeling of c-myc-deregulating chromosomal translocations. <i>Oncogene</i> , 1997, 15, 2369-2377.	2.6	46
25	AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. <i>Journal of Experimental Medicine</i> , 2007, 204, 2989-3001.	4.2	45
26	A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma. <i>Cancer Research</i> , 2007, 67, 4069-4078.	0.4	43
27	Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?. <i>Oncotarget</i> , 2015, 6, 40496-40506.	0.8	42
28	PIAS1 Promotes Lymphomagenesis through MYC Upregulation. <i>Cell Reports</i> , 2016, 15, 2266-2278.	2.9	39
29	Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. <i>Blood</i> , 2005, 105, 2135-2137.	0.6	38
30	Selenium Deficiency Abrogates Inflammation-Dependent Plasma Cell Tumors in Mice. <i>Cancer Research</i> , 2004, 64, 2910-2917.	0.4	35
31	Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. <i>British Journal of Haematology</i> , 2007, 138, 349-353.	1.2	33
32	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 507-515.	3.0	33
33	CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. <i>Molecular Cancer</i> , 2021, 20, 84.	7.9	33
34	RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF- κ B Activation and Lymphoma Survival. <i>Molecular and Cellular Biology</i> , 2015, 35, 3324-3338.	1.1	28
35	Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms. <i>International Journal of Molecular Sciences</i> , 2012, 13, 6204-6219.	1.8	27
36	NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3313-3325.	5.7	27

#	ARTICLE	IF	CITATIONS
37	Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. <i>Oncogene</i> , 2002, 21, 7235-7240.	2.6	26
38	Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells. <i>Cancer Research</i> , 2007, 67, 2439-2447.	0.4	26
39	Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 436, 660-665.	1.0	26
40	BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. <i>Cancer Research</i> , 2003, 63, 8656-63.	0.4	26
41	Conformational differences in the 3-D nanostructure of the immunoglobulin heavy-chain locus, a hotspot of chromosomal translocations in B lymphocytes. <i>Cancer Genetics and Cytogenetics</i> , 2001, 127, 168-173.	1.0	24
42	Insertion of <i>c-Myc</i> into <i>Igh</i> Accelerates Peritoneal Plasmacytomas in Mice. <i>Cancer Research</i> , 2005, 65, 7644-7652.	0.4	24
43	Deregulation of <i>c-Myc</i> Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors. <i>Journal of Immunology</i> , 2008, 181, 7537-7549.	0.4	24
44	Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 548, 117-125.	0.4	23
45	t(14;18) Translocations and Risk of Follicular Lymphoma. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 48-51.	0.9	23
46	Waldenström Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models. <i>ISRN Hematology</i> , 2013, 2013, 1-25.	1.6	23
47	Modulation of the H ₂ O ₂ -induced SOS response in <i>Escherichia coli</i> PQ300 by amino acids, metal chelators, antioxidants, and scavengers of reactive oxygen species. <i>Environmental and Molecular Mutagenesis</i> , 1993, 22, 157-163.	0.9	22
48	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	2.8	22
49	Forkhead Box M1 Regulates Quiescence-Associated Radioresistance of Human Head and Neck Squamous Carcinoma Cells. <i>Radiation Research</i> , 2014, 182, 420.	0.7	21
50	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. <i>BMC Cancer</i> , 2018, 18, 1152.	1.1	21
51	Moderate G6PD deficiency increases mutation rates in the brain of mice. <i>Free Radical Biology and Medicine</i> , 2002, 32, 663-673.	1.3	20
52	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 225-231.	1.3	17
53	FOXM1 regulates glycolysis and energy production in multiple myeloma. <i>Oncogene</i> , 2022, 41, 3899-3911.	2.6	16
54	In a model of immunoglobulin heavy-chain (<i>IGH</i>)/ <i>MYC</i> translocation, the <i>Igh</i> regulatory region induces <i>MYC</i> expression at the immature stage of B cell development. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 950-959.	1.5	15

#	ARTICLE	IF	CITATIONS
55	Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. <i>Blood Cancer Journal</i> , 2018, 8, 22.	2.8	15
56	Assessment of oxidative DNA damage in theoxyR-deficient sos chromotest strains <i>Escherichia coli</i> PQ300. <i>Environmental and Molecular Mutagenesis</i> , 1992, 20, 297-306.	0.9	14
57	Paradoxical decrease in mutant frequencies and chromosomal rearrangements in a transgenic lacZ reporter gene in Ku80 null mice deficient in DNA double strand break repair. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 529, 51-58.	0.4	14
58	CDDO-Imidazole inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. <i>Molecular Cancer</i> , 2006, 5, 22.	7.9	14
59	Coactivation of NF- κ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , 2020, 135, 108-120.	0.6	14
60	Jumping Translocation Breakpoint Regions Lead to Amplification of Rearranged Myc. <i>Blood</i> , 1999, 93, 4442-4444.	0.6	13
61	Suppression of steroid 5 α -reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. <i>Cell Death and Disease</i> , 2021, 12, 206.	2.7	13
62	Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. <i>PLoS ONE</i> , 2013, 8, e76889.	1.1	13
63	Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 70-74.	1.5	12
64	CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2015, 4, 9.	2.0	12
65	Non-Hodgkin Lymphomas of Mice. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 217-222.	0.6	11
66	Autonomic nervous system control of multiple myeloma. <i>Blood Reviews</i> , 2021, 46, 100741.	2.8	11
67	Uncovering MYC's full oncogenic potential in the hematopoietic system. <i>Oncogene</i> , 2005, 24, 3541-3543.	2.6	10
68	Germline Risk Contribution to Genomic Instability in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2019, 10, 424.	1.1	10
69	Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 316, R678-R686.	0.9	10
70	TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	10
71	Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. <i>Genes Chromosomes and Cancer</i> , 2001, 30, 283-291.	1.5	9
72	Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. <i>BMC Genomics</i> , 2007, 8, 302.	1.2	9

#	ARTICLE	IF	CITATIONS
73	WDR26 and MTF2 are therapeutic targets in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 203.	6.9	8
74	Extrasosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 137-146.	1.5	7
75	Genetic and Environmental Cofactors of Myc Translocations in Plasma Cell Tumor Development in Mice. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 37-40.	0.9	7
76	NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas. <i>PLoS ONE</i> , 2014, 9, e112126.	1.1	7
77	DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. <i>Immunogenetics</i> , 1996, 44, 151-156.	1.2	6
78	I μ 4/SI μ 4 transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells. <i>Oncogene</i> , 2003, 22, 2842-2850.	2.6	6
79	Moderate Hypermutability of a Transgenic lacZ Reporter Gene in Myc-Dependent Inflammation-Induced Plasma Cell Tumors in Mice. <i>Cancer Research</i> , 2004, 64, 530-537.	0.4	6
80	Location of Myc, Igh, and Igk on Robertsonian fusion chromosomes is inconsequential for Myc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors prefer Igk-Myc inversions over translocations. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 416-426.	1.5	6
81	Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. <i>Molecular Cancer</i> , 2005, 4, 40.	7.9	6
82	Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. <i>Blood</i> , 2012, 119, 1018-1028.	0.6	6
83	Myeloma sleeper agent in myeloid disguise. <i>Blood</i> , 2019, 134, 3-4.	0.6	6
84	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	2.0	6
85	Isotype switch-mediated CH deletions are a recurrent feature of Myc/CH translocations in peritoneal plasmacytomas in mice. <i>International Journal of Cancer</i> , 2002, 101, 423-426.	2.3	5
86	A new model of LMP1-MYC interaction in B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2917-2923.	0.6	5
87	Elevated mutant frequencies in gene lacI in splenic lipopolysaccharide blasts after exposure to activated phagocytes in vitro. <i>European Journal of Immunology</i> , 1997, 27, 2160-2164.	1.6	4
88	Overview of Mechanisms and Consequences of Chromosomal Translocation. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 1-1.	0.9	4
89	Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. <i>Haematologica</i> , 2020, 105, e111-e115.	1.7	4
90	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	0.7	4

#	ARTICLE	IF	CITATIONS
91	Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma. <i>Blood</i> , 2021, 138, 2802-2802.	0.6	4
92	Transgenic Shuttle Vector Assays for Determining Genetic Differences in Oxidative B Cell Mutagenesis in Vivo. <i>Methods in Enzymology</i> , 2002, 353, 434-448.	0.4	3
93	Anaplastic plasmacytoma of mouse establishing parallels between subtypes of mouse and human plasma cell neoplasia. <i>Journal of Pathology</i> , 2010, 221, 242-247.	2.1	3
94	Mouse Models of Human Mature B-Cell and Plasma Cell Neoplasms. , 2008, , 179-225.		3
95	Migration of Cells With Immunoglobulin/c-myc Recombinations in Lymphoid Tissues of Mice. <i>Blood</i> , 1997, 89, 291-296.	0.6	3
96	Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 502-510.	1.9	3
97	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	3
98	Bcl-2 reduces mutant rates in a transgenic lacZ reporter gene in mouse pre-B lymphocytes. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 522, 135-144.	0.4	2
99	Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 667054.	2.2	2
100	Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca/Bcl-XL Plasma Cell Malignancy.. <i>Blood</i> , 2009, 114, 3835-3835.	0.6	2
101	NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2671-2671.	0.6	2
102	Completion of the DNA sequence determination of the lgh2 locus of the mouse: the 5'-IA region. <i>Immunogenetics</i> , 1995, 43, 101-4.	1.2	1
103	Mouse model of MYD88L265P-dependent DLBCL. <i>Blood</i> , 2016, 127, 2660-2661.	0.6	1
104	MYC needs MNT to drive B cells over the edge. <i>Blood</i> , 2020, 135, 977-978.	0.6	1
105	MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.. <i>Blood</i> , 2009, 114, 1834-1834.	0.6	1
106	The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.. <i>Blood</i> , 2009, 114, 3849-3849.	0.6	1
107	FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma. <i>Blood</i> , 2016, 128, 4456-4456.	0.6	1
108	Distinct MYC thresholds in hematopoietic neoplasia. <i>Blood</i> , 2006, 108, 413-413.	0.6	0

#	ARTICLE	IF	CITATIONS
109	TCL1-induced germinal center B lymphomas in mice. Blood, 2006, 108, 1791-1792.	0.6	0
110	Response to Guglielmi et al., "The 3' IgH regulatory region is active at immature stages of B cell development". Genes Chromosomes and Cancer, 2008, 47, 94-94.	1.5	0
111	New wrinkle on deubiquitination in B-cell lymphoma. Blood, 2018, 132, 2529-2530.	0.6	0
112	Dkk1 Transgenic Mice for the Study of Bone Lesions in Human Multiple Myeloma.. Blood, 2005, 106, 2505-2505.	0.6	0
113	IL-6 and Tumor Susceptibility Alleles of Strain BALB/C Cause Phenotypic Shift of MYC-Driven Lymphomas in Mice from Diffuse Large B-Cell Lymphoma (DLBCL) to Plasmacytoma (PCT). Blood, 2008, 112, 5316-5316.	0.6	0
114	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Blood, 2021, 138, 4091-4091.	0.6	0
115	DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. Immunogenetics, 1996, 44, 151-156.	1.2	0